ADPT: Bullish Pennant detected on 6 May 2026

ADPT is forming a bullish pennant after a sharp three-month decline of 25.51%. The pattern shows solid structure (13.0/15) with the stock consolidating between support at $12.36 and resistance at $15.61, currently trading at $13.78. Volume scores a strong 12.0/12, with today's 3.13M shares traded representing a 1.92x volume multiple above the 20-day average—critical for pennant confirmation. The breakout score of 13.0/13 and overall score of 77.0/98 suggest a technically sound setup. RSI at 46.65 is neutral, neither overbought nor oversold, positioning well for an upside move. The stock sits 64.54% above its 52-week low, indicating recovery momentum from depressed levels.

Adaptive Biotechnologies is a Seattle-based immunotherapy company focused on T-cell receptor sequencing and clonal diversity analysis. The biotech sector remains under pressure—the Health Care sector regime shows a bearish regime score of -0.0, reflecting broader biotech headwinds around FDA approvals and funding tightness. Recent biotech volatility has weighed on ADPT's valuation. The stock's 33.62% discount to its 52-week high reflects sector-wide selloffs rather than company-specific catastrophe. No major catalyst announcements have emerged in recent weeks to explain the immediate three-month decline, suggesting this consolidation may represent exhausted selling pressure. The bullish market regime (score 0.86) provides macro tailwind for reversal patterns, even as biotech faces structural challenges.

A successful breakout above $15.61 resistance would target $14.81 conservatively (measured move calculation), with potential for continuation toward the 52-week highs. Volume confirmation is critical—breakout requires sustained volume above 1.6M shares daily to validate the pennant resolution. The pattern's 61.23% win probability suggests better-than-coin-flip odds, though this is not dominant conviction. Invalidation occurs decisively below $12.36 support, where the lower pennant boundary breaks and the consolidation fails. This would signal sellers retained control and the three-month decline resumes. Traders should watch for volume expansion on any breakout attempt; weak breakouts (low volume) tend to reverse quickly in pennant setups.

Several risks warrant caution. The Health Care sector regime is bearish (score -0.0), creating headwinds even for bullish technical patterns—sector rotation could overwhelm stock-specific setups. ATR volatility of 5.01% is moderate-to-elevated, and beta of 1.13 means ADPT amplifies broader market swings. Recent two-week and one-month returns are negative despite technical stabilization, suggesting weak underlying momentum. A potential unknown risk: no recent earnings date or major news catalyst surfaced in searches, raising questions about what fundamental developments justify a reversal. If earnings disappointment or clinical trial setback emerges, the pattern breaks immediately. The stock remains 33% below 52-week highs, and short interest or insider selling would be material red flags not visible in technical data alone. Biotech funding environment remains constrained.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.